Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somavaratan versus daily recombinant human growth hormone in prepubertal children with growth hormone deficiency
2014-004525-41Phase 3Completed
- Sponsor
- Versartis, Inc.
- Start
- Feb 2015
- Modality
- Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in growth hormone deficiency (GHD) comparing Somavaratan arm with Daily recombinant human growth hormone arm (2 arms). Primary endpoint: Annual height velocity. Started Feb 2015; status: completed.
02
Drugs
somavaratansomatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2014-004525-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004525-41.